Fibroblast Growth Factor (FGF): How It Works, Types, Skincare Benefits, Hair Growth, and What the Research Shows

FGF is one of those topics where the science is genuinely interesting but the marketing around it — particularly in skincare — often overpromises. This guide covers what the research actually shows, what is established, and what is still experimental.

Fibroblast Growth Factors are a family of signaling proteins that play a fundamental role in how the human body grows, heals, and maintains itself throughout life. From regulating embryonic development to controlling tissue repair in adults, and even linking with advanced treatments like enzyme replacement therapy, FGFs touch nearly every major biological process in the body, from influencing skin aging to managing glucose and fat metabolism, FGFs touch nearly every major biological process in the body.

This guide covers the complete picture: what FGFs are at a molecular level, the 22 members of the family and what each does, the science behind their role in skincare and hair growth, FDA-approved medical applications, what the research genuinely shows versus what is still speculative, and the risks associated with FGF-based therapies.

What Is Fibroblast Growth Factor?

Fibroblast Growth Factors (FGFs) are a family of 22 structurally related polypeptide signaling proteins that exert their biological effects by binding to four specific cell surface receptors — FGFR1, FGFR2, FGFR3, and FGFR4. When an FGF molecule binds to its receptor, it triggers a cascade of intracellular signaling events that regulate gene expression, influencing whether cells grow, divide, migrate, differentiate, or undergo programmed death.

The name ‘fibroblast growth factor’ comes from the early observation that these proteins stimulate the proliferation of fibroblasts — the cells responsible for producing collagen and other connective tissue components. However, FGFs are not limited to fibroblasts. They act on virtually every cell type in the body, making them one of the most pleiotropic (wide-ranging) protein families in human biology.

FGFs are produced by a wide range of cell types throughout the body and are active during both development and adult tissue maintenance. Their activity requires heparan sulfate proteoglycans as co-receptors — meaning these proteins work alongside the extracellular matrix to coordinate their signals precisely.

The 22 Types of Fibroblast Growth Factors — What Each Does

The FGF family divides into subfamilies based on sequence similarity, receptor binding preference, and mechanism of action. Some FGFs act locally (paracrine or autocrine signaling), while others circulate in the bloodstream as hormones (endocrine FGFs).

FGF	Common Name	Primary Biological Role	Clinical/Research Relevance
FGF1	Acidic FGF	Angiogenesis, cell proliferation, wound healing	Wound healing therapies, cardiovascular research
FGF2	Basic FGF (bFGF)	Angiogenesis, tissue repair, neural development	Most widely used in research; wound healing, corneal repair
FGF3	INT-2	Embryonic development	Implicated in some cancers
FGF4	HST/KFGF	Embryonic limb and heart development	Cancer research — amplified in some tumors
FGF7	KGF (Keratinocyte Growth Factor)	Skin keratinocyte proliferation, hair follicle activation	FDA-approved: Palifermin (Kepivance) for mucositis
FGF8	Androgen-induced GF	Brain, limb, and heart embryonic development	Neural development research
FGF9	GAF	Lung, joint, and testicular development	Lung disease research
FGF10	KGF-2	Lung branching, skin wound healing, hair follicle development	Skin wound healing, hair loss research
FGF13	FHF2	Neuronal function, cardiac rhythm	Cardiac arrhythmia research
FGF14	FHF4	Neuronal activity regulation	Cerebellar ataxia research
FGF19	FGF15 in mice	Bile acid synthesis regulation, intestinal hormone	Liver disease, metabolic research
FGF21	—	Glucose and fat metabolism, energy homeostasis	Active clinical trials for NASH, obesity, type 2 diabetes
FGF23	—	Phosphate and vitamin D regulation	Linked to chronic kidney disease, FGF23-related rickets

How FGF Receptors Work — The Signal Mechanism

Understanding how FGFs actually produce their effects requires a brief look at receptor biology. The four FGF receptors (FGFR1–4) are transmembrane tyrosine kinase receptors — proteins that span the cell membrane with an extracellular binding domain and an intracellular enzymatic domain.

When an FGF molecule binds to its receptor, it causes receptor dimerization — two receptor molecules pair together. This pairing activates the intracellular kinase domains, which phosphorylate each other and initiate downstream signaling cascades including the RAS/MAPK pathway (cell proliferation), PI3K/AKT pathway (cell survival), and STAT pathway (gene transcription).

The specificity of FGF signaling — meaning why different FGFs produce different effects in different tissues — comes from the combination of which FGF is present, which receptor isoform is expressed in that tissue, and what heparan sulfate structures are available in the local extracellular matrix. This precise spatial and tissue-specific control explains how one large protein family can coordinate such diverse biological processes.

FGFR mutations are clinically significant. Gain-of-function mutations in FGFR3, for example, cause achondroplasia — the most common form of dwarfism. Activating mutations in FGFRs also drive several cancers, including bladder cancer, cholangiocarcinoma, and multiple myeloma — making FGFRs important cancer drug targets.

Fibroblast Growth Factor in Skincare — What the Science Shows

FGF-based skincare has attracted significant commercial interest because FGFs — particularly FGF1, FGF2, and FGF7 — play direct roles in skin cell turnover, collagen production, and wound repair. Understanding what the evidence actually supports helps distinguish genuine benefit from marketing claims.

How FGF Affects Skin Biology

• Collagen and elastin stimulation: FGF2 (basic FGF) stimulates fibroblasts to produce collagen and elastin — the structural proteins responsible for skin firmness and elasticity. As FGF2 levels naturally decline with age, collagen synthesis slows, contributing to wrinkle formation and skin laxity.
• Keratinocyte proliferation: FGF7 (keratinocyte growth factor) specifically drives the proliferation of keratinocytes — the dominant cell type in the epidermis. Faster keratinocyte turnover improves skin texture, reduces hyperpigmentation, and accelerates healing after procedures.
• Angiogenesis: FGF1 and FGF2 stimulate new blood vessel formation in the dermis, improving nutrient and oxygen delivery to skin cells — contributing to a healthier complexion.
• Post-procedure healing: FGF-containing creams and serums are used in some dermatology practices after laser resurfacing, microneedling, and chemical peels to accelerate recovery, reduce post-inflammatory hyperpigmentation, and improve the quality of healing skin.

What the Clinical Evidence Shows

Several controlled clinical studies have examined topical FGF formulations. A 2015 randomized controlled trial published in the Journal of Cosmetic Dermatology demonstrated that a topical cream containing recombinant human FGF significantly reduced wrinkle depth and improved skin elasticity compared to placebo after 12 weeks. A 2020 study found that combined microneedling with topical FGF produced superior outcomes for atrophic acne scars compared to microneedling alone.

However, important caveats apply: topical FGF molecules are large proteins and face significant challenges penetrating intact skin. The stratum corneum (outer skin barrier) limits the penetration of proteins, which means much of the FGF in topical products may not reach the target dermal fibroblasts. Delivery methods — including nano-encapsulation and post-procedure application when the barrier is temporarily disrupted — are active areas of research to address this limitation.

FGF vs EGF in Skincare — Which Is Better?

Feature	FGF (Fibroblast Growth Factor)	EGF (Epidermal Growth Factor)
Primary target cells	Fibroblasts, keratinocytes	Keratinocytes, epithelial cells
Main skin benefit	Collagen stimulation, deep dermis repair	Surface cell turnover, epidermis renewal
Wound healing	Strong — both dermal and epidermal	Primarily epidermal
Anti-aging mechanism	Increases collagen and elastin in dermis	Accelerates epidermal cell renewal
Post-procedure use	Well-supported for laser and microneedling	Well-supported for all resurfacing
Research maturity	Moderate — growing body of evidence	More established — longer history
Commercial availability	Less common in OTC products	Widely available in serums and creams

In practice, skincare formulations increasingly combine FGF and EGF with other growth factors (TGF-beta, VEGF, PDGF) because each targets different aspects of skin repair and the combination produces synergistic effects that neither alone achieves.

Fibroblast Growth Factor and Hair Loss — What the Research Shows

Hair follicle biology depends heavily on FGF signaling, particularly FGF7 (KGF) and FGF10, which support the anagen (growth) phase of the hair cycle. Disruption of FGF signaling in hair follicles contributes to follicle miniaturization — the progressive shrinking seen in androgenetic alopecia (male and female pattern hair loss).

Mechanisms of FGF Action in Hair Follicles

• FGF7 and FGF10 activate hair follicle stem cells: These growth factors stimulate the keratinocyte stem cells in the hair follicle bulge region — the reservoir of cells responsible for hair regrowth during each new hair cycle.
• FGF2 promotes dermal papilla cell survival: Dermal papilla cells (DPCs) at the base of the follicle orchestrate the hair growth cycle. FGF2 supports DPC proliferation and prevents their premature apoptosis.
• FGF5 regulates the catagen transition: Interestingly, FGF5 acts as a natural inhibitor of hair growth — it signals the transition from anagen (growth) to catagen (regression). FGF5 inhibition is therefore a therapeutic target for extending the hair growth phase. Some topical hair growth formulations include FGF5 inhibitors alongside FGF7 activators.
• FGF-10 promotes new follicle development: Research in wound healing has shown that FGF10 can stimulate de novo (new) hair follicle formation in adult skin — a finding with significant implications for hair restoration.

Clinical Evidence for FGF in Hair Growth

A 2019 study published in Pharmaceutical Biology demonstrated that plant-derived FGF7 inducers promoted hair regrowth and increased anagen phase duration in C57BL/6 mice. A 2022 study examined the combination of microneedling with topical FGF versus minoxidil for androgenetic alopecia, finding comparable efficacy in hair density improvement at 24 weeks.

FGF-based hair growth formulations are currently available as topical serums in several markets, though none carry FDA approval for hair loss treatment as of 2025. Clinical trials investigating FGF peptide formulations for alopecia are ongoing. Minoxidil and finasteride remain the only FDA-approved pharmacological treatments for androgenetic alopecia.

FGF21 — The Metabolic FGF Getting the Most Research Attention

Among all 22 FGF family members, FGF21 has attracted by far the most pharmaceutical interest in recent years. Unlike most FGFs that act locally, FGF21 functions as an endocrine hormone — it is produced primarily by the liver and circulates in the bloodstream to regulate energy metabolism in multiple tissues.

FGF21 increases insulin sensitivity, promotes fat burning (fatty acid oxidation), suppresses appetite, regulates circadian rhythm, and modulates lipid metabolism. Plasma FGF21 levels rise in response to prolonged fasting, carbohydrate restriction, and high-fat diets — suggesting it plays a key role in the metabolic response to nutritional stress.

FGF21 Clinical Trial Pipeline

• NASH (Non-Alcoholic Steatohepatitis): Several FGF21 analogs — including pegbelfermin (BMS-986036) and efruxifermin — are in Phase 2 and Phase 3 clinical trials for NASH, showing significant reductions in liver fat and fibrosis markers in clinical studies, which are commonly monitored using SGOT SGPT liver test..
• Type 2 diabetes and obesity: FGF21 analogs improve glycemic control and produce clinically meaningful reductions in body weight in diabetic patients, positioning them as potential next-generation metabolic drugs.
• Mixed dyslipidemia: FGF21 analogs show potent triglyceride-lowering and HDL-raising effects, with one analog (LY3552799) in active trials for cardiovascular risk reduction.

FGF21-based drugs are investigational. None have received FDA approval as of 2025. Efruxifermin received FDA Breakthrough Therapy designation for NASH in 2021.

FGF23 — The Bone and Kidney Hormone

FGF23 is produced by bone cells (osteocytes and osteoblasts) and functions as a hormone that regulates phosphate homeostasis and vitamin D metabolism. It acts on the kidneys to increase phosphate excretion in the urine and suppress activation of vitamin D.

Elevated FGF23 levels are strongly associated with chronic kidney disease (CKD) and independently predict cardiovascular mortality in CKD patients. Genetic mutations causing FGF23 excess produce X-linked hypophosphatemia (XLH) — a condition causing rickets and bone deformities due to phosphate wasting.

Burosumab (Crysvita) — an anti-FGF23 monoclonal antibody — received FDA approval in 2018 for X-linked hypophosphatemia, marking the first approved therapy directly targeting an FGF family member.

FDA-Approved Therapies Involving FGF Pathways

Drug	FGF Target	Approved Indication	Approval Year
Palifermin (Kepivance)	FGF7 agonist	Oral mucositis in cancer patients undergoing stem cell transplant	2004
Burosumab (Crysvita)	Anti-FGF23 antibody	X-linked hypophosphatemia (XLH) and FGF23-related hypophosphatemia	2018
Erdafitinib (Balversa)	FGFR1-4 inhibitor	Metastatic urothelial carcinoma with FGFR2/3 alterations	2019
Pemigatinib (Pemazyre)	FGFR1/2/3 inhibitor	Cholangiocarcinoma with FGFR2 fusions	2020
Infigratinib (Truseltiq)	FGFR1/2/3 inhibitor	Cholangiocarcinoma with FGFR2 fusions	2021
Futibatinib (Lytgobi)	FGFR1-4 inhibitor	Intrahepatic cholangiocarcinoma with FGFR2 fusions	2022
Vofatamab (investigational)	FGFR3 inhibitor	Urothelial cancer — Phase 3 trials	Not yet approved

The gap between the established clinical uses of FGF (cancer treatment, rare bone disease) and the consumer-facing claims (wrinkle reduction, hair growth) is wider than most skincare marketing acknowledges. The science is real — the translation to consumer products is still in progress

An important observation from this table: the majority of FDA-approved FGF-pathway drugs are FGFR inhibitors for cancer treatment — not FGF activators for skincare or hair growth. The therapeutic applications most commonly marketed to consumers (anti-aging serums, hair growth products) represent the less clinically established end of FGF science.

Risks and Side Effects of FGF-Based Therapies

FGF signaling drives cell proliferation — and this creates an inherent tension in therapeutic applications. The same pathways that promote tissue repair and regeneration can, under certain conditions, promote uncontrolled cell growth.

• Cancer risk with unregulated use: Because FGFs stimulate cell proliferation, supraphysiological FGF administration theoretically carries cancer risk — particularly in individuals with pre-existing precancerous lesions. This risk is most relevant for systemic or injectable FGF applications, not standard topical cosmetic formulations at regulated concentrations.
• FGFR inhibitor side effects: FDA-approved FGFR inhibitor drugs (cancer treatments) produce class-specific side effects including hyperphosphatemia, nail toxicity, dry eyes, liver enzyme elevations, and hand-foot skin reactions.
• Topical skin reactions: Some individuals experience contact dermatitis, redness, or irritation from FGF-containing topical products. Patch testing before full-face application is advisable.
• Wound healing overstimulation: Excess FGF2 signaling has been associated with hypertrophic scarring in some wound healing research — the same mechanism that promotes healing can, in excess, contribute to excessive scar tissue formation.
• Long-term safety data for cosmetic use: Long-term human safety data for regular topical FGF use in cosmetics is limited. Most available studies run for 12–24 weeks. The safety profile beyond this timeframe has not been comprehensively evaluated.

Frequently Asked Questions

Is FGF the same as EGF in skincare products?

No — FGF (fibroblast growth factor) and EGF (epidermal growth factor) are different protein families that act on different receptors. Both have roles in skin cell proliferation and wound healing, but they target different cell populations and operate through different signaling pathways. EGF primarily targets keratinocytes (surface skin cells), while FGF works more broadly including on fibroblasts (collagen-producing cells deeper in the dermis). Many advanced skincare formulations include both alongside other growth factors for synergistic effect.

Can FGF regrow hair on completely bald areas?

The honest answer is: probably not in areas of complete follicle loss. FGF7 and FGF10 work by activating existing hair follicle stem cells and supporting follicle cycling — they cannot create new follicles from scratch in areas where follicles have been permanently destroyed (as in end-stage scarring alopecia or fully miniaturized follicles). Research on de novo follicle generation with FGF10 in wound healing models is intriguing but has not translated to clinical hair restoration applications. For existing thinning, FGF-based formulations may support hair density alongside evidence-based treatments.

Do FGF skincare products actually work?

The scientific rationale for FGF in skincare is sound — FGFs genuinely regulate collagen production, skin cell turnover, and wound healing. The question is delivery. Topical application of large protein molecules faces significant skin barrier penetration challenges. Post-procedure application (after microneedling or laser treatment when the barrier is temporarily open) likely delivers FGF to target cells more effectively than application to intact skin. Products that combine FGF with penetration-enhancing technology or use nano-encapsulation show more promise than standard formulations. As with many skincare actives, results vary significantly between individuals.

What is FGF21 and why do researchers find it so exciting?

FGF21 is a liver-produced hormone that regulates glucose and fat metabolism. It improves insulin sensitivity, promotes fat burning, suppresses appetite, and beneficially affects lipid levels. Its pharmaceutical potential lies in treating metabolic diseases — NASH (fatty liver with inflammation), type 2 diabetes, and obesity — where current treatment options remain limited. Several FGF21 analogs are in advanced clinical trials, and the FDA granted Breakthrough Therapy designation to efruxifermin for NASH in 2021. FGF21 also rises naturally with exercise and fasting — similar to metabolic signaling seen with MOTS-c peptide. — one reason some longevity researchers consider it a mediator of the metabolic benefits of those interventions.

Are FGF supplements worth taking?

Oral FGF supplements face the same problem as oral peptide supplements generally — FGF proteins are broken down by digestive enzymes in the stomach and intestine before reaching systemic circulation. An FGF capsule does not deliver intact FGF protein to your skin or other tissues. Some supplements claim to ‘support’ FGF production through precursor nutrients — these claims are largely unsubstantiated. The most evidence-supported ways to support endogenous FGF activity include regular exercise, adequate protein intake, and maintaining healthy metabolic function.

Key Takeaways

• Fibroblast Growth Factors are a family of 22 signaling proteins that regulate cell growth, tissue repair, metabolism, and development throughout life.
• FGF2 (basic FGF) and FGF7 (KGF) are the most relevant for skincare — stimulating collagen production, keratinocyte turnover, and wound healing.
• FGF7 and FGF10 support hair follicle stem cell activation and hair cycle progression — with most evidence supporting their role in preventing further miniaturization rather than regrowing completely lost hair.
• FGF21 is the metabolic FGF attracting the most pharmaceutical research — with clinical trials for NASH, type 2 diabetes, and obesity showing promising results.
• FDA-approved FGF-pathway drugs exist for X-linked hypophosphatemia (burosumab), cancer (FGFR inhibitors), and oral mucositis (palifermin) — but not for skincare or hair loss.
• The cancer risk concern with FGF is most relevant for systemic/injectable use at supraphysiological doses — not standard topical cosmetic concentrations.
• Topical delivery of FGF faces skin barrier penetration challenges — post-procedure application or encapsulated formulations are more likely to deliver meaningful amounts to target cells.

FGF research is moving quickly — particularly FGF21 in metabolic disease. We will update this guide as new clinical trial results and FDA decisions emerge. The underlying biology is compelling; what the approved clinical applications will eventually look like is still being written

References

• Ornitz DM, Itoh N. The Fibroblast Growth Factor signaling pathway. Wiley Interdiscip Rev Dev Biol. 2015.
• Wang H et al. FGF21: A Novel Regulator of Glucose and Lipid Metabolism. Frontiers in Endocrinology. 2022. PubMed: 35413740
• Lee CJ et al. Eclipta prostrata promotes hair regrowth and induces FGF-7 in C57BL/6 mice. Pharmaceutical Biology. 2019.
• FDA Drug Approvals: Burosumab (Crysvita), Palifermin (Kepivance), Erdafitinib (Balversa). fda.gov
• Belov AA, Mohammadi M. Molecular mechanisms of fibroblast growth factor signaling in physiology and pathology. Cold Spring Harb Perspect Biol. 2013.

About this article:

Prepared by the LabCare Editorial Team, drawing on 14+ years of experience in the diagnostic laboratory industry. All health and science content is reviewed for factual accuracy before publication.

Disclaimer: This article is for educational and informational purposes only and does not constitute medical advice. FGF-based skincare products and hair growth formulations are not FDA-approved treatments for any medical condition. Always consult a qualified healthcare professional before starting any new therapy or supplement.